Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2010

01-01-2010 | Original paper

Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk

Authors: Elisabeth Feik, Andreas Baierl, Barbara Hieger, Gerhard Führlinger, Astrid Pentz, Stefan Stättner, Werner Weiss, Thomas Pulgram, Gernot Leeb, Karl Mach, Michael Micksche, Andrea Gsur

Published in: Cancer Causes & Control | Issue 1/2010

Login to get access

Abstract

Purpose

Insulin-like growth factor 1 (IGF1) is a peptide growth factor that promotes cell proliferation and inhibits apoptosis. The bioavailability of IGF1 is regulated by the insulin-like growth factor binding protein 3 (IGFBP3). The purpose of this study was to examine the association of genetic variants in IGF1 (rs6214, rs6220, and rs35767) and IGFBP3 (rs2854744 and rs2854746) with risk of colorectal polyps and colorectal cancer.

Methods

In this ongoing colorectal cancer study of Austria (CORSA), a total of 3,360 Caucasian participants, consisting of 178 colorectal cancer patients, 328 patients with high risk polyps, 1,059 patients with low risk colorectal polyps, and 1,795 colonoscopy-negative controls, were recruited within a large colorectal screening project in the province Burgenland and from three hospitals in Vienna. Multiple logistic regression was applied to compare individuals of the control group against three different risk groups, namely, colorectal cancer group, high risk polyp group, and low risk polyp group.

Results

Carriers of the homozygous polymorphic genotype of the SNP rs6214 were associated with an increased colorectal risk (OR = 1.79, 95% CI 1.04–1.90) compared to the colonoscopy-negative controls; this was also found when combining colorectal cancer cases and high risk polyp group (OR = 1.39, 95% CI 1.01–1.90).

Conclusion

Our results suggest that the SNP rs6214 of IGF1 could have an impact on developing colorectal cancer and colorectal polyps with villous elements.
Literature
1.
Vutuc C, Waldhoer T, Haidinger G, Ahmad F, Micksche M (1999) The burden of cancer in Austria. Eur J Cancer Prev 8(1):49–55CrossRefPubMed
2.
Bustin SA, Jenkins PJ (2001) The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med 7(10):447–454CrossRefPubMed
3.
Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76(4):1005–1026PubMed
4.
Jenkins PJ, Mukherjee A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol (Oxf) 64(2):115–121CrossRef
5.
Rodriguez S, Gaunt TR, Day IN (2007) Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum Genet 122(1):1–21CrossRefPubMed
6.
Baxter RC (1994) Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42(4–5):140–144CrossRefPubMed
7.
Samani AA, Brodt P (2001) The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am 10(2):289–312, viiiPubMed
8.
Probst-Hensch NM, Yuan JM, Stanczyk FZ et al (2001) IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85(11):1695–1699CrossRefPubMed
9.
Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91(7):620–625CrossRefPubMed
10.
Thissen JP, Ketelslegers JM, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15(1):80–101PubMed
11.
Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60(1):91–106CrossRefPubMed
12.
Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U (1996) Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81(5):1791–1797CrossRefPubMed
13.
Harrela M, Koistinen H, Kaprio J et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98(11):2612–2615CrossRefPubMed
14.
Scheet P, Stephens M (2006) A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 78(4):629–644CrossRefPubMed
15.
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265CrossRefPubMed
16.
Winawer SJ, Zauber AG, Fletcher RH et al (2006) Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 56(3):143–159 quiz 184–185CrossRefPubMed
17.
18.
Tomlinson I, Webb E, Carvajal-Carmona L et al (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39(8):984–988CrossRefPubMed
19.
Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10:353–358
20.
Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94(2):299–307CrossRefPubMed
21.
Palles C, Johnson N, Coupland B et al (2008) Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet 17(10):1457–1464CrossRefPubMed
22.
Al-Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15(1):1–10CrossRefPubMed
23.
Deal C, Ma J, Wilkin F et al (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86(3):1274–1280CrossRefPubMed
24.
Pechlivanis S, Wagner K, Chang-Claude J et al (2007) Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detect Prev 31(5):408–416CrossRefPubMed
Metadata
Title
Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Authors
Elisabeth Feik
Andreas Baierl
Barbara Hieger
Gerhard Führlinger
Astrid Pentz
Stefan Stättner
Werner Weiss
Thomas Pulgram
Gernot Leeb
Karl Mach
Michael Micksche
Andrea Gsur
Publication date
01-01-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9438-4

Other articles of this Issue 1/2010

Cancer Causes & Control 1/2010 Go to the issue

Original paper

Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma

Original paper

Screening mammography intervals among postmenopausal hormone therapy users and nonusers

Original paper

The association between fruit and vegetable consumption and HPV viral load in high-risk HPV-positive women with cervical intraepithelial neoplasia

Original paper

Atrophic gastritis and the risk of incident colorectal cancer

Original Paper

Metabolic syndrome components and colorectal adenoma in the CLUE II cohort

Original paper

Leukocyte telomere length in a population-based case–control study of ovarian cancer: a pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits